Targeting the RhoA pathway inhibitors may be helpful for patients with IPF, as AKAP13 interacts with both protein kinase A and the Rho/Rac family of guanosine triphosphate binding proteins [37]. This evidence concerns the gene AKAP13 and idiopathic pulmonary fibrosis.